Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 196pembrolizumab 188Carboplatin 163Biopsy 130Cisplatin 129Nivolumab 121Paclitaxel 110Cyclophosphamide 107Radiotherapy 101Gemcitabine 96Dexamethasone 89durvalumab 85atezolizumab 71Rituximab 66Radiation 65Lenalidomide 64Doxorubicin 64Pemetrexed 61Bevacizumab 59Etoposide 56Docetaxel 55olaparib 53Ipilimumab 51Taxes 48Prednisone 48Fluorouracil 47venetoclax 46Cytarabine 46Vincristine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pamidronate × 90 days × Clear all
NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡